➢ To establish normative date
|
|
● Breed and size variations |
|
● Age |
|
● Gender |
|
● Within subject functional and anatomical asymmetry [75] |
|
➢ To provide a baseline
|
|
● At initial diagnosis and for serial comparison, for example, if develops drug-resistant epilepsy |
|
➢ To identify patients with poor prognosis / less likely to respond to treatment
|
|
● Volume compared to normative data |
|
● Within subject asymmetry in volume |
|
➢ Improving cohort selection for entry into clinical trials evaluating
|
|
● Antiepileptic drugs |
|
● Neuro-protective agents that may modulate the consequences of epilepsy on cognition and behaviour [76] |
|
● Novel treatment modalities |
|